NFATC4

Across TCGA pan-cancer cohorts, NFATC4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NFATC4 data layer compared with 18 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NFATC4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NFATC4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where NFATC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.830	0.350	.001	58	view →
PDAC	OS	Quartile	All	0.330	0.667	.005	25	view →
LSCC	DFS	Quartile	II,III,IV	0.546	0.920	.004	24	view →
GBM	DFS	Tertile	All	0.202	0.370	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NFATC4–CCRCC (DFS)

Open the CCRCC breakdown →